FDA Panel Backs Human Genome Sciences, Inc.'s Drug, Benlysta for Lupus

Wall Street Journal -- Experimental lupus drug Benlysta — co-developed by Human Genome Sciences and GlaxoSmithKline — moved one step closer to approval yesterday. An FDA advisory panel voted to recommend approval by a sizeable margin: 13-2, as the WSJ reports.

Back to news